Attovia Therapeutics(NASDAQ) ATTO

Attovia Therapeutics makes medicines for people with skin and immune diseases. Their treatments help stop constant itching and painful inflammation. The company uses a special technology to create these new drugs.

A Pipeline for Relief

• ATTO-1310: Therapeutic targeting interleukin-31, a protein that causes itching; completed Phase 1 clinical trials in early 2026.
• ATTO-2306: Bispecific drug candidate targeting two different inflammatory proteins simultaneously; currently in studies to support human testing.
• ATTO-1091: Trispecific fusion protein designed to block three distinct immune pathways; expected to enter clinical trials in 2027.
• ATTOBODY Platform: Licensed technology used to rapidly discover and build these complex biological medicines.

Major Moves and Partnerships

• In-licensed the ATTOBODY antibody engineering platform from Alamar Biosciences in June 2023.
• Entered a worldwide license agreement with EndPath RadioTherapeutics for radioligand technology in July 2025.
• Completed an initial public offering on Aug. 6, 2026, raising $305.4 million in net proceeds.
• Nominated three specific drug candidates for development within the first two years of operations.

What Makes Attovia Unique

The company uses an evolution-driven process to create biparatopic biologics. These medicines can bind to targets in multiple ways to treat complex diseases.

The Numbers Behind the Science

• Net loss was $39.3 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $115.1 million as of June 30, 2026.
• Collaboration revenue from the EndPath agreement reached $500,000 for the six months ended June 30, 2026.
• Accumulated deficit grew to $150.4 million as of June 30, 2026.
• Management estimates existing funds and IPO proceeds will support operations into 2030.

Bottom Line

Attovia has transitioned from a platform-focused startup to a clinical-stage developer with three lead programs. Its reliance on a high-throughput discovery engine supports its efforts to address unmet needs in inflammatory diseases.